Insmed Inc (INSM)vsRallybio Corp (RLYB)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
RLYB
Rallybio Corp
$8.63
-0.52%
HEALTHCARE · Cap: $48.19M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 70579% more annual revenue ($606.42M vs $858,000). RLYB leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
RLYB
Hold37
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
4.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : RLYB
The strongest argument for RLYB centers on Price/Book, Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : RLYB
The primary concerns for RLYB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while RLYB is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
RLYB is growing revenue faster at 4.8% — sustainability is the question.
RLYB generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 37/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Rallybio Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases, specifically targeting unmet medical needs in immunology and hematology. The company boasts a robust pipeline of biologic drug candidates advancing through clinical stages, supported by a seasoned management team with strong industry expertise. Strategic collaborations strengthen Rallybio's capabilities in delivering transformative treatments, ultimately aiming to enhance patient outcomes. With a clear commitment to underserved therapeutic areas, Rallybio is well-positioned to make significant contributions to the healthcare sector while paving the way toward commercial success.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?